EpCAM (KSA) Peptide & DC Cancer Vaccine Development

Creative Biolabs provides comprehensive preclinical development services for KSA-based cancer vaccines, covering antigen characterization, epitope mapping, anti-idiotypic antibody design, peptide and protein vaccine formulation, dendritic cell (DC)-based loading, in vitro immunogenicity assessment, and in vivo efficacy evaluation. KSA, also known as epithelial glycoprotein (EGP) or epithelial cell adhesion molecule (EpCAM), is a 40 kDa transmembrane glycoprotein overexpressed on the surface of most adenocarcinomas—including colorectal, gastric, pancreatic, breast, lung, and prostate cancers. This solution is designed for researchers developing tumor-associated antigen (TAA) vaccines, validating KSA-specific T-cell responses, optimizing anti-idiotypic strategies, or evaluating combination approaches with immune checkpoint inhibitors. Our scientists can provide customized study designs, assay development, quality control, and integrated preclinical packages tailored to your tumor indication, antigen format, and translational goals.

KSA (EpCAM): A Compelling TAA Target for Adenocarcinoma Vaccines

From Adhesion Molecule to Vaccine Antigen

KSA (EpCAM) is a type I transmembrane glycoprotein belonging to a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein of neuroectodermal origin. In normal epithelial tissues, KSA is expressed in a polarized manner at the basolateral membrane, where it contributes to cell-cell adhesion and maintains tissue architecture. Upon malignant transformation, this polarized distribution is lost; KSA becomes homogeneously distributed across the entire tumor cell membrane, mirroring the expression pattern changes observed with carcinoembryonic antigen (CEA). This redistribution exposes previously sequestered epitopes to immune surveillance, making KSA an attractive target for active immunotherapy.

Why Target KSA for Vaccination?
KSA is overexpressed in over 90% of colorectal and gastric adenocarcinomas, and its expression is retained in metastatic lesions and circulating tumor cells. Anti-KSA antibodies have been detected in patients following anti-idiotypic antibody vaccination, confirming that KSA is immunogenic in humans without detectable toxicity to normal tissues.

Core Preclinical Challenges We Address:
Selecting immunodominant KSA epitopes restricted by common HLA alleles.
Breaking tolerance to a self-antigen through optimized adjuvant and carrier strategies.
Designing anti-idiotypic antibodies that mimic KSA conformational epitopes.
Distinguishing anti-tumor immunity from on-target, off-tumor reactivity in vivo.

KSA Expression: Normal Epithelium vs. Adenocarcinoma

Key Comparison	Normal Epithelial Tissue	Adenocarcinoma (KSA-Positive)
Membrane Distribution	Polarized; restricted to basolateral surface.	Homogeneous; circumferential membrane staining.
Expression Level	Moderate; varies by tissue type.	Markedly upregulated; retained in metastases.
Epitope Accessibility	Sequestered by tight junctions; limited immune access.	Fully exposed to antibody and T-cell recognition.
Cancer Stem Cell Association	Not applicable.	Enriched on CSC populations; targets tumor-initiating cells.

End-to-End KSA Vaccine Service Packages

Our preclinical services are structured into flexible, modular packages. We understand that every project is unique; therefore, all modules can be fully customized—from epitope selection to vaccine formulation and animal model choice—to align with your therapeutic goals and tumor indications.

Strategy

Antigen Evaluation & Epitope Mapping

Comprehensive analysis of KSA antigenic structure to identify the most immunogenic epitopes for vaccine design.

Expression Profiling: Verification of KSA expression levels across target adenocarcinoma cell lines and patient-derived samples.
Epitope Prediction: Bioinformatics-driven identification of HLA-A2 and other allele-restricted KSA peptide epitopes.
Binding Affinity: Peptide-T2 binding assays to rank epitopes by MHC class I binding strength.
Conformational Mapping: Identification of discontinuous B-cell epitopes recognized by anti-KSA monoclonal antibodies (17-1A, KS1/4).

Discovery

Anti-Idiotypic Antibody Design

Development of anti-idiotypic antibodies that function as internal images of KSA, enabling active immunization without administering the tumor antigen itself.

Mimotope Selection: Screening phage display libraries for antibody fragments that mimic KSA conformational epitopes.
Cross-Reactivity: Validation that anti-idiotypic antibodies elicit sera capable of binding native KSA on tumor cells.
Immunogenicity Screening: In vitro B-cell activation assays to confirm humoral response induction.
Carrier Optimization: Conjugation to carrier proteins (KLH, CRM197) to enhance T-helper dependent responses.

Engineering

Vaccine Construct Production

Synthesis and assembly of KSA vaccine candidates across multiple platforms tailored to your immunization strategy.

Peptide Vaccines: Production of multi-epitope synthetic long peptide (SLP) pools spanning immunodominant KSA regions.
Protein Vaccines: Recombinant KSA ectodomain production in mammalian or insect expression systems.
DNA/RNA Vaccines: Construction of plasmid or mRNA vectors encoding KSA for endogenous antigen expression.
Viral Vectors: Generation of recombinant viral vectors (adenoviral, vaccinia-based) carrying KSA transgenes.

Construction

DC-Based KSA Vaccine Formulation

Specialized dendritic cell loading and maturation protocols to maximize KSA-specific T-cell priming.

Peptide Pulsing: Optimization of KSA peptide loading onto monocyte-derived DCs for MHC class I and II presentation.
mRNA Electroporation: Transfection of DCs with KSA-encoding mRNA for sustained endogenous antigen processing.
Maturation Cocktails: TLR agonist and cytokine combinations to drive CD80/CD86 co-stimulatory marker expression.
Adjuvant Screening: Evaluation of immunostimulatory adjuvants to break self-tolerance and enhance immunogenicity.

Potency

Comprehensive Potency Evaluation

Multi-level assessment of vaccine-induced humoral and cellular anti-tumor immune responses.

Humoral Assays: ELISA and flow cytometry to quantify anti-KSA antibody titers and tumor cell surface binding.
Cellular Assays: ELISpot (IFN-γ), intracellular cytokine staining, and DC-T co-culture cytotoxicity assays.
In Vivo POC: Efficacy studies in syngeneic or humanized mouse models bearing KSA-expressing tumors.
Immune Profiling: Tumor-infiltrating lymphocyte analysis, cytokine monitoring, and survival tracking.

Support

QC & Translational Data Packages

Quality assurance and comprehensive documentation to support translational advancement of KSA vaccine candidates.

Antigen Characterization: Purity, endotoxin, and stability testing of vaccine constructs.
DC Phenotyping: Flow cytometry verification of CD11c, HLA-DR, CD80, CD83, and CD86 expression.
Lot Consistency: Reproducibility assessment across independent vaccine preparations.
Safety Screening: Preliminary toxicology and off-target reactivity assessments in relevant in vitro panels.

Preclinical KSA Vaccine Development Workflow

Phase 1 — KSA Antigen Characterization & Epitope Selection

We begin by confirming KSA (EpCAM) expression on your target adenocarcinoma cell lines or patient-derived xenograft samples. Using bioinformatics prediction tools and peptide-T2 binding assays, we identify HLA-A2-restricted KSA peptide epitopes with high MHC binding affinity. Conformational B-cell epitopes recognized by established anti-KSA monoclonal antibodies (17-1A, KS1/4) are also mapped to guide anti-idiotypic antibody design.

Phase 2 — Vaccine Construct Design & Strategy

Based on the selected epitopes, we design the optimal vaccine format—peptide pools, recombinant protein, DNA/mRNA vectors, viral vectors, or anti-idiotypic antibody mimics. Adjuvant and carrier protein selection is tailored to break self-tolerance against this ubiquitously expressed epithelial antigen. For DC-based approaches, maturation cocktail composition and antigen loading method (peptide pulsing vs. mRNA electroporation) are finalized.

Phase 3 — Immunogen Production & Formulation

Vaccine constructs are synthesized to high purity using validated expression and purification platforms. Peptide pools are manufactured by solid-phase synthesis with endotoxin removal. Recombinant KSA ectodomain is produced in mammalian or insect cell systems. DC vaccines are prepared by isolating CD14+ monocytes, differentiating them into immature DCs, and loading with KSA antigens followed by maturation with optimized TLR agonist and cytokine cocktails.

Phase 4 — In Vitro Immunogenicity Assessment

Vaccine candidates are evaluated for their capacity to elicit KSA-specific immune responses. Humoral responses are measured by ELISA (anti-KSA IgG titers) and flow cytometry (binding to KSA+ tumor cells). Cellular responses are assessed using ELISpot for IFN-γ secretion, intracellular cytokine staining for CD8+ T-cell activation, and DC-T co-culture cytotoxicity assays against KSA-expressing tumor cell lines such as HepG2 and colorectal adenocarcinoma lines.

Phase 5 — In Vivo Efficacy & Safety Evaluation

Lead vaccine candidates are tested in syngeneic or humanized mouse models bearing KSA-expressing tumors. Endpoints include tumor growth inhibition, survival benefit, infiltration of CD8+ T cells into tumor tissue, and reduction of KSA+ cancer stem cell populations. Safety assessments evaluate potential on-target reactivity against normal epithelial tissues, ensuring a sufficient therapeutic window for the vaccine approach.

Enabling Technologies for KSA Vaccine Development

Anti-Idiotypic Antibody Platform

Phage display and hybridoma-based screening to generate anti-idiotypic antibodies that serve as internal images of KSA conformational epitopes. These mimetics enable active immunization without direct administration of tumor-derived antigen, reducing the risk of tolerance induction.

Peptide-DC Loading Technology

Optimized protocols for pulsing monocyte-derived dendritic cells with HLA-A2-restricted KSA peptides or electroporating with KSA-encoding mRNA. Maturation cocktails featuring TLR agonists ensure high CD80/CD86 expression and IL-12 secretion for potent T-cell priming.

Syngeneic & Humanized Tumor Models

A panel of immunocompetent syngeneic mouse models and humanized mouse systems bearing KSA-expressing adenocarcinoma xenografts. These models enable rigorous evaluation of vaccine-induced tumor regression, immune memory, and combination efficacy with checkpoint inhibitors.

Why Choose Creative Biolabs?

Deep TAA Vaccine Expertise

Years of focused experience in tumor-associated antigen vaccine development, with particular strength in epithelial antigens including KSA, CEA, and MUC1.

Multi-Platform Flexibility

From peptide and protein vaccines to DC-based formulations and anti-idiotypic approaches, we offer the full spectrum of vaccine modalities under one roof.

Customized Immunogenicity Assays

Our assay development team builds project-specific readouts—ELISpot, cytotoxicity, antibody binding—that precisely measure KSA-directed immune responses.

End-to-End Project Continuity

From antigen evaluation through in vivo efficacy, we provide a single integrated workflow with rigorous QC, complete documentation, and dedicated scientific communication.

Research Insight: EpCAM Peptide-DC Vaccination in Hepatocellular Carcinoma

Key Findings from Preclinical Studies

EpCAM (KSA) peptide-primed dendritic cell vaccination has demonstrated significant anti-tumor immunity in preclinical hepatocellular carcinoma models, providing a strong rationale for expanding KSA-targeted vaccine strategies across adenocarcinoma indications.

Efficient CTL Induction: EpCAM peptides with high HLA-A2 binding affinity, when loaded onto monocyte-derived DCs, generated potent cytotoxic T lymphocytes that specifically killed EpCAM+ HepG2 tumor cells in vitro.¹
In Vivo Tumor Growth Inhibition: Vaccination of tumor-bearing mice with EpCAM peptide-CTLs significantly delayed HepG2 tumor growth, with reduced EpCAM expression in residual tumor tissue confirmed by immunohistochemistry.¹
Bispecific T-Cell Engager Synergy: Oncolytic vaccinia virus engineered to promote EpCAM-directed T-cell engagement enhanced intratumoral CD8+ T-cell infiltration and reduced T-cell exhaustion, supporting its potential synergy with KSA vaccine strategies.²
Broad Adenocarcinoma Applicability: EpCAM-targeted T-cell–engaging immunotherapies have been investigated across multiple epithelial cancer types, including pancreatic, colorectal, and gastric adenocarcinomas, supporting KSA as a broadly relevant target across adenocarcinomas.

EpCAM BiTE-mediated activation of naïve T cells promotes tumor cell killing.

Fig.1 Secreted EpCAM-targeted T-cell–engaging molecules activate naïve T cells and induce cytotoxicity against tumor cells.^{2, 3}

FAQs Regarding KSA Vaccine Services

KSA (Kirsten sarcoma-associated antigen) is a historical name for the human adenocarcinoma-associated antigen, also known as epithelial glycoprotein (EGP) or epithelial cell adhesion molecule (EpCAM). They refer to the same 40 kDa transmembrane glycoprotein overexpressed on most adenocarcinomas. The different names reflect the independent discovery and characterization paths that identified this antigen through monoclonal antibodies such as 17-1A, KS1/4, and GA733.

KSA (EpCAM) is overexpressed in a broad range of adenocarcinomas, including colorectal, gastric, pancreatic, breast, lung, prostate, and ovarian cancers. Expression is typically confirmed at the protein level by flow cytometry or immunohistochemistry before initiating vaccine development. Our team can help assess KSA expression on your specific cell lines or patient-derived samples to determine feasibility.

Since KSA is a self-antigen expressed on normal epithelial tissues, breaking tolerance is a central challenge. We employ several strategies: using anti-idiotypic antibodies that mimic KSA without being identical to the self-protein; selecting high-affinity HLA-restricted peptides that may not be presented under normal physiological conditions; optimizing adjuvant formulations with TLR agonists; and employing DC-based platforms that provide strong co-stimulatory signals to overcome anergy.

We utilize both syngeneic mouse models with murine EpCAM-expressing tumor cell lines and humanized mouse models bearing human KSA+ adenocarcinoma xenografts. For DC-based vaccines, bone marrow-derived DCs (BMDCs) from immunocompetent mice are used for in vivo proof-of-concept studies. Endpoints include tumor volume, survival, intratumoral CD8+ T-cell density, and circulating anti-KSA antibody titers.

Yes. Combination of KSA vaccines with immune checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) is an actively explored strategy. Vaccination primes KSA-specific T cells, while checkpoint blockade releases inhibitory signals in the tumor microenvironment. We can design combination dosing schedules and evaluate endpoints such as tumor regression, TIL density, and T-cell exhaustion markers in in vivo models.

Related Resources

Scientific References

Choi, Yoo Jin, et al. "EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells." PLOS ONE 13.1 (2018): e0190638.https://doi.org/10.1371/journal.pone.0190638
Wei, Min, et al. "Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors." Frontiers in Immunology 13 (2022): 1017574.https://doi.org/10.3389/fimmu.2022.1017574
Distributed under Open Access License CC BY 4.0, without modification.